In this review, we set out to highlight the importance of the JAK/STAT pathway during Alzheimer’s disease development and discuss the feasibility of targeting the JAK/STAT pathway as a potential neuroprotective therapy. Here, SOAT1 is linked to early-onset autosomal dominant Alzheimer disease.